Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 75th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 301.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
In the past 5.5 years, Horizon Therapeutics Public Ltd Co has a compound free cash flow growth rate of 1%; that's higher than 87.84% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 11% of the company's capital (with equity being the remaining amount). Approximately only 23.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 111 -- greater than 97.14% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See LXRX, CI, MYL, AMEH, and CVS.
HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear's team has made significant progress and the company will receive an undisclosed milestone payment in accordance with the agreement with Horizon, which was executed in January 2019.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
I first wrote about Horizon Therapeutics (HZNP) back in April and had initiated a full position in the company around the time of publication. Since then, Horizon reported its first-quarter results, and its stock has seen a substantial move. This article provides an update on what has changed for the...